ClinicalTrials.gg
TerminatedNCT02993783Updated May 24, 2019Results posted

A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)

A Phase 2 interventional study of Vedolizumab in Allogeneic Hematopoietic Stem Cell Transplantation, sponsored by Millennium Pharmaceuticals, Inc.. Terminated at 15 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-24.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 2, Interventional, and Treatment

Why this study was terminated
Lack of efficacy of the drug; no safety concern

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the initial activity, tolerability, safety and to identify a recommended dose and regimen of vedolizumab intravenous (IV) administered for treatment of steroid-refractory acute intestinal GvHD in participants who have undergone allo-HSCT.

Read the detailed description

The drug being tested in this study is called vedolizumab. This study will look at the tolerability and effectiveness of vedolizumab IV in participants with acute intestinal GvHD who have received no systemic therapy for the treatment of acute GvHD (prophylaxis acceptable) other than corticosteroids.

The study enrolled 17 participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups:

  • Vedolizumab 300 mg
  • Vedolizumab 600 mg

All participants will be infused intravenously at the same time each day throughout the study. Vedolizumab IV will be administered on Days 1, 15, 43, 71, and 99. After approximately 10 participants are enrolled at each dose level and have data available from the Day 28 evaluation, safety, tolerability, efficacy, and pharmacokinetic (PK), results will be assessed for each dose level, and the appropriate dose for subsequent participants in the study will be determined.

This multi-center trial will be conducted in multiple countries. The overall time to participate in this study is 32 weeks. Participants will make multiple visits to the clinic after last dose of study drug for a follow-up assessment.

02

Conditions studied

  • Allogeneic Hematopoietic Stem Cell Transplantation

Keywords

  • Drug Therapy
03

In context

Lead sponsor

Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.

Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.

First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Recipient of 1 hematopoietic stem cell transplantation (allo-HSCT) but not more than 1 allo-HSCT.
  2. Has primary - (GvHD). Steroid-refractory disease is defined as worsening or no improvement in 5 to 7 days of treatment with methylprednisolone 2 milligram per kilogram (mg/kg) or equivalent or lack of a CR after 14 days of primary treatment with methylprednisolone 2 mg/kg or equivalent. Note that participants who develop intestinal GvHD while receiving systemic therapy for other GvHD are still eligible after 5 to 7 days, even if the intestinal GvHD has not been present for the entire duration. Participants who may have received an increase in their steroid dose treatment (example, increased methylprednisolone from 1 mg/kg to 2 mg/kg) before enrollment will be eligible, provided the participant has met the definition of steroid refractory above. Participants who develop toxicity on corticosteroids or who are otherwise medically unable to be dosed to this level, will also be eligible.
  3. (ECOG) performance status of 0 to 3.
  4. Evidence of myeloid engraftment defined by greater than or equal to (>=) 0.5*109/liter (L) on 3 consecutive days.

Exclusion criteria

Exclusion Criteria:

  1. Presence of chronic GvHD at Screening (including acute-chronic overlap syndrome).
  2. Relapse of underlying malignant disease after .
  3. Hyperacute GvHD defined as onset of GvHD within the first 15 days following hematopoietic stem cell infusion.
  4. Received systemic agents other than for treatment of acute GvHD. GvHD prophylaxis agents (example, calcineurin inhibitors) may be continued.
  5. of \<3 weeks.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Vedolizumab 300 mg

    Vedolizumab 300 mg, intravenous (IV) infusion, once on Days 1, 15, 43, 71 and 99.

    Drug: Vedolizumab

  • Experimental
    Vedolizumab 600 mg

    Vedolizumab 600 mg, IV infusion, once on Days 1, 15, 43, 71 and 99.

    Drug: Vedolizumab

Interventions

  • Vedolizumab IV infusion

    Also known as: Entyvio, MLN0002

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Overall Response (Partial Response [PR]+Very Good Partial Response [VGPR]+Complete Response [CR]) at Day 28

    CR is defined as the resolution of all signs and symptoms of acute graft-versus-host-disease (GvHD). VGPR is defined as resolution of the signs and symptoms of the GvHD: 1) Skin: no rash, or residual erythematous rash involving \<25% of the body surface, without bullae (excluding residual faint erythema and hyperpigmentation). 2) Liver: total serum bilirubin concentration \<2 mg/dL or \<25% of baseline at enrollment. 3) Gut: a) participant tolerates food or enteral feeding; b) predominantly formed stools; c) no overt gastrointestinal bleeding or abdominal cramping; d) no more than occasional nausea or vomiting. PR is defined as improvement of 1 GvHD stage in 1 or more organs without progression in any organ.

    Time frame: Day 28

  2. Number of Participants Who Experienced Serious Adverse Events (SAEs) Through Day 28

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as an untoward medical occurrence, significant hazard, contraindication, side effect or precaution that at any dose: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

    Time frame: From first dose up to Day 28

Secondary outcomes

  1. Percentage of Participants Who Died in the Absence of Primary Malignancy Relapse After Allo-HSCT at Month 6

    Time frame: Month 6

  2. Percentage of Participants With Acute GvHD Complete Response (CR) at Day 28

    CR is defined as the resolution of all signs and symptoms of acute GvHD.

    Time frame: Day 28

  3. Percentage of Participants With Intestinal Overall Response at Day 28

    Symptoms of acute intestinal GvHD were measured using the BMT CTN-modified International Bone Marrow Transplant Registry Database (IBMTR) index. Intestinal overall response is either CR, VGPR or PR for intestine only. CR is defined as the resolution of all signs and symptoms of GvHD. VGPR is defined as resolution of the majority of signs and symptoms of intestinal GvHD: a) participant tolerates food or enteral feeding; b) predominantly formed stools; c) no overt gastrointestinal bleeding or abdominal cramping; d) no more than occasional nausea or vomiting. PR is defined as improvement of intestinal GvHD by at least 1 stage.

    Time frame: Day 28

  4. Kaplan-Meier Estimate of Percentage of Participants Achieving Survival at Months 6 and 12

    The Kaplan-Meier estimate reports the percentage of participants surviving at Months 6 and 12.

    Time frame: Months 6 and 12

  5. Percentage of Participants Alive Without GvHD or Primary Malignancy Relapse at Months 6 and 12

    Time frame: Months 6 and 12

  6. Total Dose of Steroids Administered

    Total Steroids administered in mg/kg/day of methylprednisolone or equivalent

    Time frame: From first dose of study drug up to Months 6 and 12

  7. Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs)

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: From first dose of study drug to 18 weeks after last dose (Up to Week 32)

  8. Number of Participants Who Experienced Serious Adverse Events (SAEs) Through Week 32

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as an untoward medical occurrence, significant hazard, contraindication, side effect or precaution that at any dose: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

    Time frame: From first dose of study drug to 18 weeks after last dose (Up to Week 32)

  9. Number of Participants With Markedly Abnormal Laboratory Parameters Values

    Clinical Laboratory parameters included tests for chemistry, hematology and urinalysis. Markedly abnormal values during treatment period were categorized as:alanine aminotransferase (ALT)\>3.0 U/L\*upper limit of normal(ULN),albumin\<25 g/L\*lower limit of normal(LLN),alkaline phosphatase \>3.0 U/L\*ULN,aspartate aminotransferase \>3.0 U/L\*ULN,bilirubin \>2 umol/L\*ULN,blood urea nitrogen(BUN) \>10.7 mmol/L,calcium \<1.75 mmol/L, \>2.88 mmol/L,chloride \<75 mmol/L, \>126 mmol/L,creatinine \>177umol/L,gamma glutamyl transferase (GGT) \>3 U/L\*ULN,glucose \<2.8 mmol/L, \>19.4 mmol/L,phosphate \<0.52 mmol/L, \>2.10 mmol/L,potassium\<3 mmol/L, \>6 mmol/L,sodium \<130 mmol/L, \>150 mmol/L,basophils \>3(10\^9/L)\*ULN,eosinophils \>2(10\^9/L)\*ULN,hematocrit (%) \<0.8\*LLN, \>1.2\*ULN,hemoglobin \<0.8 g/L\*LLN, \>1.2 g/L\*ULN,leukocytes \<0.5 (10\^9/L)\*LLN, \>1.5 (10\^9/L)\*ULN,lymphocytes \<0.5 (10\^9/L)\*LLN, \>1.5(10\^9/L)\*ULN,monocytes \>2 (10\^9/L)\*ULN,neutrophils \<0.5(10\^9/L)\*LLN, \>1.5 (10\^9/L)\*ULN,platelets \<75(10\^9/L), \>600(10\^9/L).

    Time frame: From Baseline up to last dose of study drug (Day 99)

  10. Number of Participants With Markedly Abnormal Vital Signs

    Vital signs included heart rate, respiratory rate, systolic and diastolic blood pressure, temperature and weight. The vital sign values outside the range: systolic blood pressure (SBP) \<85 mmHg and change from Baseline (BL) \<=-20 mmHg, \>180 mmHg and change from Baseline \>=20 mmHg,diastolic blood pressure (DBP) \<50 mmHg and change from Baseline \<=-15 mmHg, \>110 mmHg and change from Baseline \>=15 mmHg, heart rate \<50 beats per minute (bpm),\>120 beats per minute, temperature \<35.6 Degree C, \>37.7 Degree C and weight change from Baseline \<=-7 % and weight change from Baseline \>=7 % assessed during treatment period were considered markedly abnormal.

    Time frame: From Baseline up to last dose of study drug (Day 99)

  11. Ctrough: Trough Serum Concentrations of Vedolizumab

    Time frame: Day 99 (pre-dose)

07

Results

Posted May 24, 2019

Participant flow

Participants took part in the study at 11 investigative sites in the United States, France, Belgium and Norway from 28 April 2017 to 09 May 2018.

Participant flow — Overall Study
MilestoneVedolizumab 300 mgVedolizumab 600 mg
Started89
Completed20
Not completed69
Withdrew: Reason not specified69

Outcome measures

PrimaryPercentage of Participants With Overall Response (Partial Response [PR]+Very Good Partial Response [VGPR]+Complete Response [CR]) at Day 28

CR is defined as the resolution of all signs and symptoms of acute graft-versus-host-disease (GvHD). VGPR is defined as resolution of the signs and symptoms of the GvHD: 1) Skin: no rash, or residual erythematous rash involving \<25% of the body surface, without bullae (excluding residual faint erythema and hyperpigmentation). 2) Liver: total serum bilirubin concentration \<2 mg/dL or \<25% of baseline at enrollment. 3) Gut: a) participant tolerates food or enteral feeding; b) predominantly formed stools; c) no overt gastrointestinal bleeding or abdominal cramping; d) no more than occasional nausea or vomiting. PR is defined as improvement of 1 GvHD stage in 1 or more organs without progression in any organ.

Time frame:
Day 28
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Response (Partial Response [PR]+Very Good Partial Response [VGPR]+Complete Response [CR]) at Day 28
percentage of participantsVedolizumab 300 mgVedolizumab 600 mg
Percentage of Participants With Overall Response (Partial Response [PR]+Very Good Partial Response [VGPR]+Complete Response [CR]) at Day 2850.0 (15.7 to 84.3)22.2 (2.8 to 60.0)
PrimaryNumber of Participants Who Experienced Serious Adverse Events (SAEs) Through Day 28

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as an untoward medical occurrence, significant hazard, contraindication, side effect or precaution that at any dose: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

Time frame:
From first dose up to Day 28
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Serious Adverse Events (SAEs) Through Day 28
ParticipantsVedolizumab 300 mgVedolizumab 600 mg
Number of Participants Who Experienced Serious Adverse Events (SAEs) Through Day 2834
SecondaryPercentage of Participants Who Died in the Absence of Primary Malignancy Relapse After Allo-HSCT at Month 6
Time frame:
Month 6
Reported as:
Number · percentage of participants
Percentage of Participants Who Died in the Absence of Primary Malignancy Relapse After Allo-HSCT at Month 6
percentage of participantsVedolizumab 300 mgVedolizumab 600 mg
Percentage of Participants Who Died in the Absence of Primary Malignancy Relapse After Allo-HSCT at Month 650.0 (15.7 to 84.3)88.9 (68.4 to 100.0)
SecondaryPercentage of Participants With Acute GvHD Complete Response (CR) at Day 28

CR is defined as the resolution of all signs and symptoms of acute GvHD.

Time frame:
Day 28
Reported as:
Number · percentage of participants
Percentage of Participants With Acute GvHD Complete Response (CR) at Day 28
percentage of participantsVedolizumab 300 mgVedolizumab 600 mg
Percentage of Participants With Acute GvHD Complete Response (CR) at Day 2812.5 (0.3 to 52.7)0 (0 to 0)
SecondaryPercentage of Participants With Intestinal Overall Response at Day 28

Symptoms of acute intestinal GvHD were measured using the BMT CTN-modified International Bone Marrow Transplant Registry Database (IBMTR) index. Intestinal overall response is either CR, VGPR or PR for intestine only. CR is defined as the resolution of all signs and symptoms of GvHD. VGPR is defined as resolution of the majority of signs and symptoms of intestinal GvHD: a) participant tolerates food or enteral feeding; b) predominantly formed stools; c) no overt gastrointestinal bleeding or abdominal cramping; d) no more than occasional nausea or vomiting. PR is defined as improvement of intestinal GvHD by at least 1 stage.

Time frame:
Day 28
Reported as:
Number · percentage of participants
Percentage of Participants With Intestinal Overall Response at Day 28
percentage of participantsVedolizumab 300 mgVedolizumab 600 mg
Percentage of Participants With Intestinal Overall Response at Day 2862.5 (24.5 to 91.5)33.3 (7.5 to 70.1)
SecondaryKaplan-Meier Estimate of Percentage of Participants Achieving Survival at Months 6 and 12

The Kaplan-Meier estimate reports the percentage of participants surviving at Months 6 and 12.

Time frame:
Months 6 and 12
Reported as:
Number · percentage of participants
Kaplan-Meier Estimate of Percentage of Participants Achieving Survival at Months 6 and 12
percentage of participantsVedolizumab 300 mgVedolizumab 600 mg
Month 60.50 (0.15 to 0.77)0.11 (0.01 to 0.39)
Month 12NA (NA to NA)NA (NA to NA)
SecondaryPercentage of Participants Alive Without GvHD or Primary Malignancy Relapse at Months 6 and 12
Time frame:
Months 6 and 12
Reported as:
Number · percentage of participants
Percentage of Participants Alive Without GvHD or Primary Malignancy Relapse at Months 6 and 12
percentage of participantsVedolizumab 300 mgVedolizumab 600 mg
Month 637.50
Month 1200
SecondaryTotal Dose of Steroids Administered

Total Steroids administered in mg/kg/day of methylprednisolone or equivalent

Time frame:
From first dose of study drug up to Months 6 and 12
Reported as:
Mean · mg/kg/day
Total Dose of Steroids Administered
mg/kg/dayVedolizumab 300 mgVedolizumab 600 mg
Month 60.862 ± 0.63970.876 ± 0.4796
Month 120.829 ± 0.66110.876 ± 0.4798
SecondaryNumber of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs)

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
From first dose of study drug to 18 weeks after last dose (Up to Week 32)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs)
ParticipantsVedolizumab 300 mgVedolizumab 600 mg
Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs)89
SecondaryNumber of Participants Who Experienced Serious Adverse Events (SAEs) Through Week 32

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as an untoward medical occurrence, significant hazard, contraindication, side effect or precaution that at any dose: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

Time frame:
From first dose of study drug to 18 weeks after last dose (Up to Week 32)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Serious Adverse Events (SAEs) Through Week 32
ParticipantsVedolizumab 300 mgVedolizumab 600 mg
Number of Participants Who Experienced Serious Adverse Events (SAEs) Through Week 3269
SecondaryNumber of Participants With Markedly Abnormal Laboratory Parameters Values

Clinical Laboratory parameters included tests for chemistry, hematology and urinalysis. Markedly abnormal values during treatment period were categorized as:alanine aminotransferase (ALT)\>3.0 U/L\*upper limit of normal(ULN),albumin\<25 g/L\*lower limit of normal(LLN),alkaline phosphatase \>3.0 U/L\*ULN,aspartate aminotransferase \>3.0 U/L\*ULN,bilirubin \>2 umol/L\*ULN,blood urea nitrogen(BUN) \>10.7 mmol/L,calcium \<1.75 mmol/L, \>2.88 mmol/L,chloride \<75 mmol/L, \>126 mmol/L,creatinine \>177umol/L,gamma glutamyl transferase (GGT) \>3 U/L\*ULN,glucose \<2.8 mmol/L, \>19.4 mmol/L,phosphate \<0.52 mmol/L, \>2.10 mmol/L,potassium\<3 mmol/L, \>6 mmol/L,sodium \<130 mmol/L, \>150 mmol/L,basophils \>3(10\^9/L)\*ULN,eosinophils \>2(10\^9/L)\*ULN,hematocrit (%) \<0.8\*LLN, \>1.2\*ULN,hemoglobin \<0.8 g/L\*LLN, \>1.2 g/L\*ULN,leukocytes \<0.5 (10\^9/L)\*LLN, \>1.5 (10\^9/L)\*ULN,lymphocytes \<0.5 (10\^9/L)\*LLN, \>1.5(10\^9/L)\*ULN,monocytes \>2 (10\^9/L)\*ULN,neutrophils \<0.5(10\^9/L)\*LLN, \>1.5 (10\^9/L)\*ULN,platelets \<75(10\^9/L), \>600(10\^9/L).

Time frame:
From Baseline up to last dose of study drug (Day 99)
Reported as:
Count of participants · Participants
Number of Participants With Markedly Abnormal Laboratory Parameters Values
ParticipantsVedolizumab 300 mgVedolizumab 600 mg
ALT >3.0 U/L*ULN40
Albumin <25 g/L*LLN48
Alkaline phosphatase >3.0 U/L*ULN10
Aspartate aminotransferase >3.0 U/L*ULN10
Bilirubin >2 umol/L*ULN12
BUN >10.7 mmol/L36
Calcium <1.75 mmol/L03
Calcium >2.88 mmol/L00
Chloride <75 mmol/L00
Chloride >126 mmol/L00
Creatinine >177umol/L01
GGT >3 U/L*ULN52
Glucose <2.8 mmol/L00
Glucose >19.4 mmol/L10
Phosphate <0.52 mmol/L00
Phosphate >2.10 mmol/L01
Potassium <3 mmol/L10
Potassium >6 mmol/L00
Sodium <130 mmol/L00
Sodium >150 mmol/L00
Basophils >3(10^9/L)*ULN00
Eosinophils >2(10^9/L)*ULN00
Hematocrit (%) <0.8*LLN78
Hematocrit (%) >1.2*ULN00
Hemoglobin <0.8 g/L*LLN78
Hemoglobin >1.2 g/L*ULN00
Leukocytes <0.5 (10^9/L)*LLN37
Leukocytes >1.5 (10^9/L)*ULN10
Lymphocytes <0.5 (10^9/L)*LLN79
Lymphocytes >1.5(10^9/L)*ULN00
Monocytes >2 (10^9/L)*ULN01
Neutrophils <0.5(10^9/L)*LLN03
Neutrophils >1.5 (10^9/L)*ULN11
Platelets <75(10^9/L)89
Platelets >600(10^9/L)00
SecondaryNumber of Participants With Markedly Abnormal Vital Signs

Vital signs included heart rate, respiratory rate, systolic and diastolic blood pressure, temperature and weight. The vital sign values outside the range: systolic blood pressure (SBP) \<85 mmHg and change from Baseline (BL) \<=-20 mmHg, \>180 mmHg and change from Baseline \>=20 mmHg,diastolic blood pressure (DBP) \<50 mmHg and change from Baseline \<=-15 mmHg, \>110 mmHg and change from Baseline \>=15 mmHg, heart rate \<50 beats per minute (bpm),\>120 beats per minute, temperature \<35.6 Degree C, \>37.7 Degree C and weight change from Baseline \<=-7 % and weight change from Baseline \>=7 % assessed during treatment period were considered markedly abnormal.

Time frame:
From Baseline up to last dose of study drug (Day 99)
Reported as:
Count of participants · Participants
Number of Participants With Markedly Abnormal Vital Signs
ParticipantsVedolizumab 300 mgVedolizumab 600 mg
SBP <85 mmHg and change from BL <=-20 mmHg00
SBP >180 mmHg and change from BL >=20 mmHg10
DBP <50 mmHg and change from BL<=-15 mmHg00
DBP >110 mmHg and change from BL>=15 mmHg00
Heart Rate <50 bpm00
Heart Rate >120 bpm01
Temperature <35.6 Degree C13
Temperature >37.7 Degree C00
Weight change from BL <=-7 %42
Weight change from BL >=7 %31
SecondaryCtrough: Trough Serum Concentrations of Vedolizumab
Time frame:
Day 99 (pre-dose)
Reported as:
Mean · ug/mL
Ctrough: Trough Serum Concentrations of Vedolizumab
ug/mLVedolizumab 300 mgVedolizumab 600 mg
Ctrough: Trough Serum Concentrations of Vedolizumab40.2 ± 37.212.3 ± 5.49

Adverse events

Collected over From first dose of study drug to 18 weeks after the last dose of study drug (Up to approximately 32 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vedolizumab 300 mg4/8 (50%)6/8 (75%)8/8 (100%)
Vedolizumab 600 mg9/9 (100%)9/9 (100%)9/9 (100%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventVedolizumab 300 mgVedolizumab 600 mg
Graft versus host diseaseImmune system disorders0/83/9
SepsisInfections and infestations2/81/9
DiarrhoeaGastrointestinal disorders1/81/9
Rectal haemorrhageGastrointestinal disorders1/80/9
DeathGeneral disorders1/80/9
Acute graft versus host disease in intestineImmune system disorders1/80/9
Bacterial sepsisInfections and infestations1/80/9
Enterococcal sepsisInfections and infestations1/81/9
Pneumonia necrotisingInfections and infestations1/80/9
UrosepsisInfections and infestations1/80/9
Most frequent other events
Showing 10 of 169
Most frequent other events
EventVedolizumab 300 mgVedolizumab 600 mg
HypokalaemiaMetabolism and nutrition disorders3/85/9
AnaemiaBlood and lymphatic system disorders4/83/9
NauseaGastrointestinal disorders3/80/9
Oedema peripheralGeneral disorders3/83/9
HyperglycaemiaMetabolism and nutrition disorders3/82/9
NeutropeniaBlood and lymphatic system disorders1/83/9
FatigueGeneral disorders0/83/9
HypoalbuminaemiaMetabolism and nutrition disorders2/83/9
HypomagnesaemiaMetabolism and nutrition disorders1/83/9
DizzinessNervous system disorders1/83/9

Baseline characteristics

Safety analysis set (SAS) included all participants who received any amount of the study drug.

Age, Continuous
Age, Continuous(years)Vedolizumab 300 mgVedolizumab 600 mgTotal
Mean54.1 ± 10.4559.0 ± 10.8756.7 ± 10.64
Sex: Female, Male
Sex: Female, Male(Participants)Vedolizumab 300 mgVedolizumab 600 mgTotal
Female6410
Male257
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Vedolizumab 300 mgVedolizumab 600 mgTotal
Not Hispanic or Latino6915
Not Reported202
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Vedolizumab 300 mgVedolizumab 600 mgTotal
White7916
Not Reported101
Region of Enrollment
Region of Enrollment(Participants)Vedolizumab 300 mgVedolizumab 600 mgTotal
Belgium224
France314
Norway011
United States358
Height
Height(cm)Vedolizumab 300 mgVedolizumab 600 mgTotal
Mean170.3 ± 12.08169.8 ± 7.87170.0 ± 9.85
Weight
Weight(kg)Vedolizumab 300 mgVedolizumab 600 mgTotal
Mean76.40 ± 16.90074.01 ± 22.25575.14 ± 19.342
Baseline Eastern Cooperative Oncology Group (ECOG) Status
Baseline Eastern Cooperative Oncology Group (ECOG) Status(Participants)Vedolizumab 300 mgVedolizumab 600 mgTotal
0202
1325
2145
3235
08

Study locations

15 sites
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Washington University
    Saint Louis, Missouri 63110, United States
  • Mount Sinai - PRIME
    Lake Success, New York 11041, United States
  • OSU - James Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
  • Baylor University Medical Center
    Dallas, Texas 75204, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • ZNA Stuivenberg
    Antwerpen, 2060, Belgium
  • AZ Sint-Jan Brugge
    Brugge, 8000, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • CHU Nantes - Hotel Dieu
    Nantes cedex 1, Loire Atlantique 44093, France
  • Hopital Claude Huriez - CHU Lille
    Lille cedex, Nord 59037, France
  • Hopital Saint-Antoine
    Paris cedex 12, Paris 75571, France
  • Oslo Universitetssykehus - Rikshospitalet
    Oslo, 3072, Norway
  • Skanes Universitetssjukhus, Lund
    Lund, 22185, Sweden
  • Akademiska Sjukhuset
    Uppsala, 75185, Sweden
09

References and documents

Publications

  • Floisand Y, Schroeder MA, Chevallier P, Selleslag D, Devine S, Renteria AS, Mohty M, Yakoub-Agha I, Chen C, Parfionovas A, Quadri S, Jansson J, Akbari M, Chen YB. A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease. Bone Marrow Transplant. 2021 Oct;56(10):2477-2488. doi: 10.1038/s41409-021-01356-0. Epub 2021 Jun 9. PubMed 34108672 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2017 to primary completion in May 2018, 12 months.

Results were first posted in May 2019, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2016
First posted
Dec 15, 2016
StartActual
Apr 28, 2017
Primary completionActual
May 9, 2018
CompletionActual
May 9, 2018
Results first posted
May 24, 2019
Last update
May 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02993783
Responsible party
Sponsor
First posted
Dec 15, 2016
Start date
Apr 28, 2017
Primary completion
May 9, 2018
Completion
May 9, 2018
Results posted
May 24, 2019
Last update
May 24, 2019

Study contacts

Study Director
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion